Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation

被引:15
作者
Porrata, Luis F. [1 ]
Inwards, David J. [1 ]
Ansell, Stephen M. [1 ]
Micallef, Ivana N. [1 ]
Johnston, Patrick B. [1 ]
Hogan, William J. [1 ]
Markovic, Svetomir N. [1 ]
机构
[1] Mayo Clin, Dept Med, Div Hematol, 200 First St SW, Rochester, MN 55905 USA
关键词
D O I
10.1155/2013/658371
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Day 100 prognostic factors of postautologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcome in classical Hodgkin lymphoma (cHL) patients have not been evaluated. Thus, we studied if the day 100 peripheral blood absolute lymphocyte/monocyte ratio (Day 100 ALC/AMC) affects clinical outcomes by landmark analysis fromday 100 postAPBHSCT. Only cHL patients achieving a complete remission at day 100 post-APBHSCT were studied. From 2000 to 2010, 131 cHL consecutive patients qualified for the study. The median followup from day 100 was 4.1 years (range: 0.2-12.3 years). Patients with a Day 100 ALC/AMC >= 1.3 experienced superior overall survival (OS) and progression-free survival (PFS) compared with Day 100 ALC/AMC < 1.3 (from day 100: OS, median not reached versus 2.8 years; 5 years OS rates of 93% (95% CI, 83%-97%) versus 35% (95% CI, 19%-51%), resp., P < 0.0001; from day 100: PFS, median not reached versus 1.2 years; 5 years PFS rates of 79% (95% CI, 69%-86%) versus 27% (95% CI, 14%-45%), resp., P < 0.0001). Day 100 ALC/AMC ratio was an independent predictor for OS and PFS. Thus, Day 100 ALC/AMC ratio is a simple biomarker that can help to assess clinical outcomes from day 100 post-APBHSCT in cHL patients.
引用
收藏
页数:8
相关论文
共 19 条
[1]   Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant [J].
Bolwell, B ;
Pohlman, B ;
Sobecks, R ;
Andresen, S ;
Brown, S ;
Rybicki, L ;
Wentling, V ;
Kalaycio, M .
BONE MARROW TRANSPLANTATION, 2004, 33 (04) :419-423
[2]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[3]   EVALUATION OF THE COULTER-COUNTER MODEL S-PLUS-IV [J].
COX, CJ ;
HABERMANN, TM ;
PAYNE, BA ;
KLEE, GG ;
PIERRE, RV .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1985, 84 (03) :297-306
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]  
DeCook L. J., 2012, BONE MARROW TRANSPLA
[6]   A prognostic score for advanced Hodgkin's disease [J].
Hasenclever, D ;
Diehl, V .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1506-1514
[7]   CD34+ cell dose and establishment of full donor chimerism at day+100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies [J].
Holtan, S. G. ;
Hogan, W. J. ;
Elliott, M. A. ;
Ansell, S. M. ;
Inwards, D. J. ;
Porrata, L. F. ;
Johnston, P. B. ;
Micallef, I. N. ;
Lacy, M. Q. ;
Gastineau, D. A. ;
Litzow, M. R. .
BONE MARROW TRANSPLANTATION, 2010, 45 (12) :1699-1703
[8]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[9]   The Ratio of the Absolute Lymphocyte Count to the Absolute Monocyte Count Is Associated with Prognosis in Hodgkin's Lymphoma: Correlation with Tumor-Associated Macrophages [J].
Koh, Young Wha ;
Kang, Hyo Jeong ;
Park, Chansik ;
Yoon, Dok Hyun ;
Kim, Shin ;
Suh, Cheolwon ;
Go, Heounjeong ;
Kim, Ji Eun ;
Kim, Chul-Woo ;
Huh, Jooryung .
ONCOLOGIST, 2012, 17 (06) :871-880
[10]  
Kohavi R, 1995, P 14 INT JOINT C ART, V2, P1137